glp-1 receptor agonists effects on cardiovascular risk reduction for the of Atherosclerotic in Patients With Type 2 Diabetes Heart transplantation in the GLP-1

Expected Weight Loss: In the head-to-head SURMOUNT-5 trial published in The New England Journal of Medicine , tirzepatide was shown to be superior to semaglutide for reduction in body weight and waist circumference at 72 weeks among adults with obesity (without diabetes)

Will small molecule oral GLP-1 receptor agonists eventually replace injectable GLP-1 receptor agonists

In vitro and ex vivo models 15 MullerT

Expert Consensus: Weight loss physicians consistently report that properly compounded tirzepatide and semaglutide from FDA-registered facilities produce results equivalent to brand-name medications

What is the GLP-1 process

Future studies should also explore the potential of emerging therapies, such as dual and triple agonists (e.g., tirzepatide and retatrutide), which have shown even greater efficacy in weight loss [20, 21]